Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
16 hedge funds and large institutions have $2.25M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
79% more capital invested
Capital invested by funds: $1.25M → $2.25M (+$993K)
60% more funds holding
Funds holding: 10 → 16 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
+$1.08M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$329K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$306K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$243K |
| 5 |
SIM
Spark Investment Management
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$471K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$37K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$11K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.76K |
OPNT Hedge Fund Activity: Q4 2017 in Review
16 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2017, worth a combined $2.25M — up 79% from $1.25M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OPNT positions and 3 closed out — a net gain of 6 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Venator Capital Management, opening a new position worth an estimated $1.08M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $471K sold.
- 16 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2017, up from 10 in Q3 2017.
- Funds reported $2.25M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 79% quarter-over-quarter.
- 9 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 3 closed out, a net change of +6 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was Venator Capital Management, an estimated $1.08M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Highland Capital Management (Texas), an estimated $471K sold.
Based on aggregated 13F filings for Q4 2017.